Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients

COVID-19 Clinical Trial

— MOPHYDA  

Official title:

A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04354597
• Other study ID #: 20 KHCC 67
• Status: Withdrawn
• Phase: N/A
• Start date: May 1, 2020
• Est. completion date: October 15, 2020

Study information

• Verified date: October 2021
• Source: King Hussein Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to assess the efficacy of the combination hydroxychloroquine and Azithromycin (HCQ and AZ) in reducing the infection risk among health care professionals in direct contact with COVID-19 patients.

Description:

Exceptional efforts have been paid globally to apply the latest and most effective means of universal standard precautions throughout the settings facing COVID-19 crisis, and this is led by health care providers who are more vulnerable and have a higher risk of getting the infection (8.3% in Italy) and a higher rate of complications and mortality with some reports suggesting high mortality among these individuals.

While several clinical trials are underway across the globe to examine the effect of chloroquine at the moment, the number of COVID-19 cases is still on the rise and health care workers are facing a very high risk of getting the infection. In this study, we aim to study prophylactic efficacy of the combination (HCQ and AZ) among health care professionals in a 16 weeks period.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 15, 2020
• Est. primary completion date: August 15, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 70 Years

Eligibility

Inclusion Criteria:

• Medical doctors, Nurses and Respiratory therapists caring for COVID-19 patients in ER and ICU and dedicated COVID19 units.

• Age between 18 and 70 years old.

• Male or non-pregnant, non- lactating female.

• Availability for follow up by phone.

• Willing to participate and provide signed informed consent.

Exclusion Criteria:

• Subjects with a history of retinopathy, sickle cell disease or trait, psoriasis, or porphyria.

• Subjects who take certain prescribed or over the counter (OTC) concomitant medication including ampicillin, cimetidine, digoxin, statins, cyclosporine, warfarin, fluconazole, within 2 weeks of dosing start, and during the duration of the study.

• Current Symptoms of Fever, Cough, or Shortness of Breath.

• PCR confirmed positive test of COVID-19.

• Weight < 40 kg.

• Pregnant (positive ß-human chorionic gonadotropin test, ß-HCG) or lactating female at the screening.

• Allergy to any of the study medications.

• History of splenectomy.

• Infection with hepatitis B or C viruses.

• Chronic or active neurologic disease including seizure disorder and chronic migraine headaches.

• Any abnormal baseline laboratory screening tests listed below

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)above twice the upper limit of normal for the reference lab.

• Creatinine above the normal range.

• Hemoglobin for males <12.5 g/dl and females <10.5 g/dl.

• Platelet count of <150 X 103/L.

• Total white blood cell (WBC) count out of normal range Note: If screening lab values are out of the normal range but are expected to be temporary (e.g. due to dehydration), they may be re-assessed one more time at the discretion of the investigator.

• An abnormal baseline screening ECG suggestive of cardiac disease as determined by a clinical investigator. QTcF of >450 msec for males and >470 msec for females.

• Any other significant finding that based on the judgment of the PI would increase the risk of having an adverse outcome from participating in this study

• Subjects known to have a mental illness

• Subjects who have Skin disorders (including rash, dermatitis, and psoriasis)

• Hematological disease.

• Cardiovascular disease.

• G6PD deficiency.

• Lactose intolerance.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• HCQ & AZ
Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.

Locations

Country	Name	City	State
Jordan	King Hussein Cancer Center	Amman

Sponsors (1)

Lead Sponsor	Collaborator
King Hussein Cancer Center

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients	Compare the proportion of participants who have RT-PCR confirmed infection with SARS-CoV-2 in both arms during the study period, measured by negative PCR test for SARS COV-2 virus	4 Months
Secondary	Safety of HCQ and AZ	Solicited and unsolicited adverse events in participants receiving HCQ+AZ during the study period, measured by the incidence of AEs in both arms. (The difference in type, number, and intensity)	4 Months
Secondary	Oxygen requirement	The proportion of participants who require oxygen therapy for any indication during the study period in both arms, measured by the requirement for O2 or not in both arms.	4 Months
Secondary	ICU admission	The proportion of participants who need ICU admission for any reason during the study period in both arms, measured by the incidence of ICU admission in both arms.	4 Months
Secondary	Mortality rate	The proportion of participants who die of any cause during the study period in both arms, measured by the incidence of death in both arms.	4 Months